Cidara Therapeutics Inc (NASDAQ:CDTX)’s share price hit a new 52-week high and low during mid-day trading on Monday . The stock traded as low as $3.75 and last traded at $3.90, with a volume of 179604 shares trading hands. The stock had previously closed at $4.00.
Several equities analysts recently issued reports on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the company a “buy” rating in a research report on Tuesday, February 27th. Zacks Investment Research cut shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, December 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $13.38.
The firm has a market capitalization of $83.08, a price-to-earnings ratio of -1.26 and a beta of 2.08. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.43 and a current ratio of 6.43.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.05. analysts forecast that Cidara Therapeutics Inc will post -2.6 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in CDTX. Prosight Management LP bought a new position in shares of Cidara Therapeutics in the fourth quarter worth approximately $11,206,000. Eversept Partners LLC bought a new position in shares of Cidara Therapeutics in the fourth quarter worth approximately $340,000. Renaissance Technologies LLC lifted its stake in shares of Cidara Therapeutics by 26.2% in the fourth quarter. Renaissance Technologies LLC now owns 179,300 shares of the biotechnology company’s stock worth $1,219,000 after buying an additional 37,197 shares in the last quarter. Broadfin Capital LLC lifted its stake in shares of Cidara Therapeutics by 4.5% in the fourth quarter. Broadfin Capital LLC now owns 857,397 shares of the biotechnology company’s stock worth $5,830,000 after buying an additional 36,994 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Cidara Therapeutics by 77.4% in the third quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock worth $328,000 after buying an additional 18,001 shares in the last quarter. Institutional investors and hedge funds own 71.87% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cidara Therapeutics (CDTX) Reaches New 12-Month High and Low at $3.75” was originally posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://theenterpriseleader.com/2018/04/02/cidara-therapeutics-cdtx-reaches-new-12-month-high-and-low-at-3-75.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.